{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116327","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.805379+00:00","generated_at":"2026-06-08T07:31:58.078601+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Barinthus Bio presents interim Phase 2b HBV003 and Phase 2a AB-729-202 data for VTP-300 in chronic HBV at AASLD","bullets":["In HBV003, 31% of participants with screening HBsAg ≤200 IU/mL had >1 log HBsAg reductions.","In AB-729-202, all VTP-300 treated patients maintained HBsAg <100 IU/mL through week 48; 60% maintained <10 IU/mL.","Seven HBV003 participants met criteria for NUC discontinuation; three discontinued NUC therapy.","No treatment-related serious adverse events were reported in either trial.","Data presented in collaboration with Arbutus Biopharma (ABUS) for imdusiran plus VTP-300 combination."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116327","json":"https://secwatch.observer/filing/0001104659-23-116327.json","markdown":"https://secwatch.observer/filing/0001104659-23-116327.md","text":"https://secwatch.observer/filing/0001104659-23-116327.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923116327/0001104659-23-116327-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923116327/tm2330270d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:31:58.078601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}